A randomized, placebo-controlled, double-blind, six-arm, dose escalation, multi-center study to evaluate the efficacy and safety of SLV306 [daglutril]: 150, 300, 600mg once daily, 150-300mg twice daily and amlodipine 5-10mg once daily in subjects with hypertension
Latest Information Update: 13 Oct 2020
At a glance
- Drugs Daglutril (Primary) ; Amlodipine
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Abbott Healthcare Products
- 02 Nov 2012 Planned number of patients 522 added as reported by EudraCT.
- 09 Nov 2006 Status change
- 29 Oct 2005 New trial record.